title: Progressive Release of Vitreomacular Traction With Aflibercept.
abstract: A patient with combined diabetic macular edema (DME) and vitreomacular traction (VMT) was treated with a series of intravitreal aflibercept (Eylea; Regeneron, Tarrytown, NY) injections. The VMT progressively released during the course of the five intravitreal injections. This release may have been spontaneous, due to a nonspecific mechanical effect from the injections, or due to a pharmacologic effect from the aflibercept. While treating DME, anti-vascular endothelial growth factor agents may have an additional benefit in releasing VMT. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:477-481.].
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Schwartz
authors.forename: Harry W
authors.initials: HW
authors.lastname: Flynn
mesh_terms: D000368:Aged; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000473:pathology*; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D041623:Tomography, Optical Coherence / Q000379:methods; D014792:Visual Acuity; D014822:Vitreous Body / Q000473:pathology*
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor